{"id":41977,"date":"2025-09-22T15:19:41","date_gmt":"2025-09-22T07:19:41","guid":{"rendered":"https:\/\/flcube.com\/?p=41977"},"modified":"2025-09-22T15:19:42","modified_gmt":"2025-09-22T07:19:42","slug":"shenzhen-salubris-submits-nmpa-nda-for-sal003-a-once%e2%80%91monthly-anti%e2%80%91pcsk9-biologic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41977","title":{"rendered":"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic"},"content":{"rendered":"\n<p><strong>Shenzhen Salubris Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002294:SHE\">SHE: 002294<\/a>) announced that it has filed a New Drug Application (NDA) with China\u2019s National Medical Products Administration (NMPA) for its proprietary Class\u202f1 biologic, <strong>SAL003<\/strong>. The recombinant fully\u2011human anti\u2011PCSK9 monoclonal antibody is designed for the treatment of hypercholesterolemia and mixed dyslipidemia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-sal003-could-disrupt-the-pcsk9-market\">Why SAL003 Could Disrupt the PCSK9 Market<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Simplified Dosing<\/strong> \u2013 Administered via a single subcutaneous injection every four weeks, contrasting with existing PCSK9 agents that require two\u2011to\u2011three injections per month or sterile compounding.<\/li>\n\n\n\n<li><strong>Cost\u2011Effective Delivery<\/strong> \u2013 A single\u2011dose regimen reduces pharmacy workload, improves patient adherence, and may lower overall treatment costs.<\/li>\n\n\n\n<li><strong>Domestic Innovation<\/strong> \u2013 Represents one of the first fully human, Class\u202f1 biologics from a Chinese manufacturer to target a globally competitive indication.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-highlights\">Development Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Origin<\/strong> \u2013 Developed entirely in\u2011house by Shenzhen Salubris, leveraging its advanced recombinant protein platform.<\/li>\n\n\n\n<li><strong>Clinical Potential<\/strong> \u2013 Early phase data suggest comparable or superior LDL\u2011cholesterol lowering efficacy relative to current anti\u2011PCSK9 therapies.<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong> \u2013 The NDA submission aligns with China\u2019s accelerated approval framework for high\u2011impact biologics, positioning SAL003 for a potential market entry in 2026.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape<\/strong> \u2013 If approved, SAL003 could challenge established players such as Repatha and Praluent, especially within China\u2019s growing lipid\u2011management market.<\/li>\n\n\n\n<li><strong>Strategic Advantage<\/strong> \u2013 A once\u2011monthly dosing schedule aligns with patient preference trends and could drive broader adoption among clinicians.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8e\u6cf0\u5361\u897f\u5355\u6297\u6ce8\u5c04\u6db2\uff08SAL003\uff09\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8e\u6cf0\u5361\u897f\u5355\u6297\u6ce8\u5c04\u6db2\uff08SAL003\uff09\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-c2f47749-9138-449c-bd76-71706759ef16\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8e\u6cf0\u5361\u897f\u5355\u6297\u6ce8\u5c04\u6db2\uff08SAL003\uff09\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\">\u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8e\u6cf0\u5361\u897f\u5355\u6297\u6ce8\u5c04\u6db2\uff08SAL003\uff09\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u4fe1\u7acb\u6cf0\uff1a\u5173\u4e8e\u6cf0\u5361\u897f\u5355\u6297\u6ce8\u5c04\u6db2\uff08SAL003\uff09\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c2f47749-9138-449c-bd76-71706759ef16\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41979,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[69,38,335,1167],"class_list":["post-41977","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cvd","tag-market-approval-filings","tag-salubris-pharmaceuticals","tag-she-002294"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug Application (NDA) with China\u2019s National Medical Products Administration (NMPA) for its proprietary Class\u202f1 biologic, SAL003. The recombinant fully\u2011human anti\u2011PCSK9 monoclonal antibody is designed for the treatment of hypercholesterolemia and mixed dyslipidemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41977\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic\" \/>\n<meta property=\"og:description\" content=\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug Application (NDA) with China\u2019s National Medical Products Administration (NMPA) for its proprietary Class\u202f1 biologic, SAL003. The recombinant fully\u2011human anti\u2011PCSK9 monoclonal antibody is designed for the treatment of hypercholesterolemia and mixed dyslipidemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41977\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-22T07:19:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-22T07:19:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2206.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic\",\"datePublished\":\"2025-09-22T07:19:41+00:00\",\"dateModified\":\"2025-09-22T07:19:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977\"},\"wordCount\":243,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2206.webp\",\"keywords\":[\"CVD\",\"Market approval filings\",\"Salubris Pharmaceuticals\",\"SHE: 002294\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41977#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41977\",\"name\":\"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2206.webp\",\"datePublished\":\"2025-09-22T07:19:41+00:00\",\"dateModified\":\"2025-09-22T07:19:42+00:00\",\"description\":\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug Application (NDA) with China\u2019s National Medical Products Administration (NMPA) for its proprietary Class\u202f1 biologic, SAL003. The recombinant fully\u2011human anti\u2011PCSK9 monoclonal antibody is designed for the treatment of hypercholesterolemia and mixed dyslipidemia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41977\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2206.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2206.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41977#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug Application (NDA) with China\u2019s National Medical Products Administration (NMPA) for its proprietary Class\u202f1 biologic, SAL003. The recombinant fully\u2011human anti\u2011PCSK9 monoclonal antibody is designed for the treatment of hypercholesterolemia and mixed dyslipidemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41977","og_locale":"en_US","og_type":"article","og_title":"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic","og_description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug Application (NDA) with China\u2019s National Medical Products Administration (NMPA) for its proprietary Class\u202f1 biologic, SAL003. The recombinant fully\u2011human anti\u2011PCSK9 monoclonal antibody is designed for the treatment of hypercholesterolemia and mixed dyslipidemia.","og_url":"https:\/\/flcube.com\/?p=41977","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-22T07:19:41+00:00","article_modified_time":"2025-09-22T07:19:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2206.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41977#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41977"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic","datePublished":"2025-09-22T07:19:41+00:00","dateModified":"2025-09-22T07:19:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41977"},"wordCount":243,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41977#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2206.webp","keywords":["CVD","Market approval filings","Salubris Pharmaceuticals","SHE: 002294"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41977#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41977","url":"https:\/\/flcube.com\/?p=41977","name":"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41977#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41977#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2206.webp","datePublished":"2025-09-22T07:19:41+00:00","dateModified":"2025-09-22T07:19:42+00:00","description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug Application (NDA) with China\u2019s National Medical Products Administration (NMPA) for its proprietary Class\u202f1 biologic, SAL003. The recombinant fully\u2011human anti\u2011PCSK9 monoclonal antibody is designed for the treatment of hypercholesterolemia and mixed dyslipidemia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41977#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41977"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41977#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2206.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2206.webp","width":1080,"height":608,"caption":"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41977#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shenzhen Salubris Submits NMPA NDA for SAL003, a Once\u2011Monthly Anti\u2011PCSK9 Biologic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2206.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41977"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41977\/revisions"}],"predecessor-version":[{"id":41980,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41977\/revisions\/41980"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41979"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}